Strategic Science & Technologies

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Strategic Science & Technologies sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).

8 total trials none currently recruiting 8 completed early-phase tilt upper quartile by trial count

Strategic Science & Technologies: 8 sponsored US clinical trials, none currently recruiting.

Strategic Science & Technologies sponsors 8 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 8 completed. 2 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Delayed Onset Muscle Soreness (DOMS), with 1 trials.

Upper-quartile sponsor footprint

Strategic Science & Technologies sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Indexed trials (enrollment closed)

8 total, page 1 of 1

COMPLETED Phase 3

Study of SST-0225 Topical Ibuprofen Cream in the Treatment of Delayed Onset Muscle Soreness (DOMS)

NCT02597634
COMPLETED Phase 2

Study to Evaluate the Efficacy and Safety of SST-6007, a Topical Sildenafil Cream, Compared to Placebo in Women With Female Sexual Arousal Disorder

NCT02570282
COMPLETED Phase 2

Phase 2a Topical Sildenafil Proof-of-Concept Study in Men With Mild to Moderate ED

NCT02390960
COMPLETED Phase 1

A Open-Label, Within-Subject Dose-Escalation Study to Evaluate the Clinical Safety and Pharmacokinetic Profile of a Topical Sildenafil Cream (5% w/w), in Healthy Postmenopausal Women

NCT02364882
COMPLETED Phase 2

Dosing Interval Study of SST-0225 Topical Ibuprofen Cream in the Treatment of Delayed Onset Muscle Soreness

NCT02339129
COMPLETED Phase 1

Open-Label, Maximum-Dose Pharmacokinetic Study of 7.5% Ibuprofen Cream (SST-0225) in Healthy Adults

NCT01986660
COMPLETED Phase 1

Single-Dose Relative Bioavailability Study of SST-6006, a Topical Sildenafil Cream Versus Oral Sildenafil in Healthy Male Adults

NCT01986673
COMPLETED Phase 3

Efficacy and Safety of SST 0225, a Topical Ibuprofen Cream, in the Treatment of Pain Associated With Acute Ankle Sprain

NCT01874626

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 3
Phase 3 2

Therapeutic Areas

Delayed Onset Muscle Soreness (DOMS) 1

How the Strategic Science & Technologies early-phase archive is shaped

8 indexed studies, none listed as recruiting (0% open); 8 completed (100%).

Phase mix: 2 late (III/IV) vs 6 early (I/II) (early-phase heavy).

Top condition: Delayed Onset Muscle Soreness (DOMS) (1 trial), 0 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Strategic Science & Technologies: archived-pipeline peers nationwide

Peers matched on 8 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Strategic Science & Technologies sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40% Total trials Recruiting share Strategic Science & TechnologiesAB ScienceAbbott Point of CareAbeona TherapeuticsAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)10xBio22nd Century Group23andMe3-C Institute for Social Development
Strategic Science & Technologies sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Strategic Science & Technologies sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 8 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Strategic Science & Technologies page

8 registered trials is a research-attention snapshot, not an endorsement of Strategic Science & Technologies or any single study.

  • None of Strategic Science & Technologies's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Delayed Onset Muscle Soreness (DOMS) is the condition Strategic Science & Technologies studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Delayed Onset Muscle Soreness (DOMS) trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Strategic Science & Technologies pipeline card: 8 registered trials from official public datasets.Report a data error.